International Stem Cell Corp. (ISCO) to Conduct Clinical Trial with One of the World’s Leading Brain Research Centers
International Stem Cell Corp., a clinical stage biotech company developing novel stem cell-based therapies, has signed a master clinical research agreement with the Florey Institute of Neuroscience and Mental Health to conduct phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in Parkinson's disease (PD) patients. ISCO said it expects to enroll all patients into the clinical trial in the first quarter of 2016, with interim results available in October. ISCO is well-paired with the Florey Institute, which is staffed with the largest neuroscience research team in Australia and ranked as one of…